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 Statins and Alzheimer’s Disease 
 Epidemiological studies indicate that statins exert a 
beneficial effect against the development of Alzheimer’s 
disease (AD)  [1–3] . While the underlying mechanisms 
are unclear, cellular and animal studies showed that 
changes in membrane cholesterol affect the proteolyt-
ic generation of amyloid-  (A  ) from the amyloid
pre cursor protein. A  is a major component of extra-
cellular plaques in AD patients and exerts neurotoxicity 
 [4–6] . Most studies indicate that lowering cholesterol
levels decreases the secretion of A  . However, moderate 
reduction of cholesterol could also promote the genera-
tion of A  in neuronal cells  [7] . The cholesterol-depen-
dent generation of A  could involve changes in the dis-
tribution of certain secretases and the amyloid precursor 
protein (APP) in distinct subcellular compartments and 
membrane microdomains/lipid rafts  [7–10] .
 Statins inhibit 3-hydroxy-3-methyl-glutaryl-coen-
zyme-A reductase (HMGCR), a rate-controlling enzyme 
in the me valonate pathway that not only produces choles-
terol, but also isoprenoids  [11] . Statins affect various 
(patho)phys iological processes, like atherosclerosis, vas-
cular in flammation, platelet activation, blood coagula-
tion, and smooth muscle cell proliferation  [12, 13] . How-
ever, the relative contribution of cholesterol and isopren-
oid metabolism to these effects is largely unknown.
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 Abstract 
 Population-based studies demonstrated that statins might 
decrease the risk of developing Alzheimer’s disease (AD). 
Statins inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme-
A reductase and thereby de novo synthesis of cholesterol. 
Cell culture and animal studies indicated that cholesterol af-
fects the proteolytic processing of the amyloid precursor 
protein and the generation of amyloid-  (A  ). Recently, we 
have demonstrated that statins can also stimulate the deg-
radation of A  . The statin-induced clearance of A  could be 
attributed to increased release of the insulin-degrading en-
zyme (IDE) via an exosome-related unconventional secre-
tory pathway. Interestingly, this statin-induced secretion of 
exosome-associated IDE was independent of cellular cho-
lesterol concentrations, but rather caused by impairment of 
isoprenoid biosynthesis and protein prenylation. We further 
identified a new hexapeptide sequence in the C-ter minal 
region of IDE, named the SlyX motif that is critically involved 
in IDE secretion. Taken these findings together, the in-
creased clearance of A  by stimulated secretion of IDE 
might contribute to the protective effects of statins against 
AD. 
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 Fig. 1. Suggested mechanism of statin-stimulated A  degradation 
by release of exosome-associated IDE. Exosomes correspond to 
intraluminal vesicles of endosomal multivesicular bodies released 
upon fusion with the plasma membrane. Isoprenoids are synthe-
sized in the mevalonate pathway. HMGCR is the rate-controlling 
enzyme in the biosynthesis of both cholesterol and isoprenoids, 
thereby regulating the isoprenylation of different proteins like 
Ras, Rab, Rho and ROCKs. Statins inhibit HMGCR, and thus also 
decrease protein prenylation. The decrease in protein prenylation 
stimulates the fusion of multivesicular bodies and release of exo-
somes containing IDE. IDE might be released upon breakage of 
exosomes allowing the degradation of extracellular A  (see text 
for details). MVBs = Multivesicular bodies. 
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 Unconventional Release of Insulin-Degrading 
Enzyme Involves Exosomes 
 Recently, we demonstrated that statins induce the re-
lease of the insulin-degrading enzyme (IDE) in associa-
tion with exosomes from microglia cells and thereby pro-
mote the clearance of extracellular A   [14] ( fig. 1 ). IDE is 
a Zn 2+ metalloproteinase and degrades insulin, but also a 
number of additional peptides, including A  .
 While mainly localized in the cytosol, IDE can also be 
released from cells and found in extracellular fluids and 
conditioned media of cultured cells  [15–17] . It lacks a 
classical signal sequence that targets it to the convention-
al secretory pathway. By utilizing bioinformatical and 
biochemical approaches, we have recently identified a 
novel motif within the inactive protease domain III of 
IDE, which we called the SlyX motif  [18] . This hexapep-
tide motif (‘EKPPHY’) shares 100% homology with an 
amino acid sequence in the C terminus of the bacterial 
SlyX protein. Its deletion significantly reduces the secre-
tion of IDE from cultured cells. In turn, fusion of the SlyX 
motif to GFP, which was expressed in the cytosol, im-
proved its secretion into the medium. Notably, the SlyX 
motif is also found in other proteins, like heparan sulfate 
proteoglycans or phospholipid scramblase 1 that undergo 
unconventional secretion pathways.
 The unconventional secretion of proteins could be me-
diated via exosomes, small 40- to 100-nm cup-shaped 
vesicles found in extracellular fluids like blood, urine, 
and cerebrospinal fluid  [19, 20] . Exosomes may modulate 
several biological processes, including inflammation, cell 
differentiation and proliferation  [20–22] . Cell biological 
studies indicate that exosomes originate from intralumi-
nal vesicles of multivesicular bodies upon fusion with the 
cellular plasma membrane  [20] . They are enriched in 
cholesterol, sphingolipids and ceramide, which are also 
present in lipid rafts and further contain certain proteins 
like Rab GTPases, flotillin, integrins and tetraspanins 
 [20] . However, little is known about the molecular ma-
chinery involved in the regulation of exosome secretion. 
Only recently has it been shown that some Rab proteins, 
like Rab35, are involved in exosome release  [23] . In addi-
tion, other prenylated proteins involved in vesicular traf-
ficking, like Ras, Rho and ROCK proteins, might also 
contribute to this pathway. Interestingly our data indicate 
that the statin-induced secretion of exosomes and the 
clearance of A  are due to the inhibition of protein pre-
nylation  [14] . Since Rab proteins are regulated by isopre-
nylation  [24] , it will be interesting to analyze whether 
statins affect the isoprenylation of certain Rab or other 
proteins, that are involved in unconventional secretion.
 Conclusions 
 The recent identification of an amino acid-based sig-
nal in IDE and its unconventional secretion via exosomes 
helped to understand the mechanisms underlying the ex-
tracellular occurrence of this enzyme. As statins strongly 
stimulate exosome release, the beneficial effects of these 
drugs against AD pathogenesis could involve stimulation 
of extracellular A  degradation. It will now be interesting 
to further characterize the identified pathway as well as 
to specifically stimulate secretion of endogenous IDE in 
therapeutic and/or preventive strategies against AD.
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